Pick a stock you “feel good” about. Pick a stock you “feel bad” about. Now ask yourself: did the feeling come before or after you looked at the numbers? If you are honest, the feeling came first; the numbers were recruited as evidence afterwards. That sequence — feel first, justify second — is the signature of one of the most powerful, most under-discussed cognitive shortcuts in behavioural finance: the Affect Heuristic, formalised by Paul Slovic, Melissa Finucane, Ellen Peters and Donald MacGregor in their landmark 2002 chapter “The Affect Heuristic” in Heuristics and Biases: The Psychology of Intuitive Judgment (Cambridge University Press), and refined further in Slovic’s 2007 paper in the European Journal of Operational Research.
For Indian retail investors — who in FY24 alone added 3.7 crore new demat accounts, who are bombarded by 15-second Instagram reels of “next multibagger” tickers, and who, per SEBI’s 24 September 2024 study, lost ₹1.81 lakh crore in equity F&O over FY22–FY24 — the affect heuristic is not academic. It is the silent operating system that converts a glossy company logo, a charismatic CEO interview, or a “feel-good” sector narrative into a buy click. This essay unpacks the academic foundations, places them in Indian market reality, gives a counter-measure checklist, links to how Graham, Buffett, Munger and Klarman dealt with it, and — as required by the editorial mandate of this publication — closes with a detailed positive case study of Titan Biotech Ltd (BSE: 524717) showing how the company’s audited FY25 numbers read as anti-affect corporate behaviour. Nothing in this essay is a buy, sell, hold, valuation or price-target call on any security.
1. What Is the Affect Heuristic?
“Affect” in psychology is the faint, almost subliminal, positive-or-negative tag the brain attaches to a stimulus within milliseconds of perceiving it. Slovic and colleagues argue that this affective tag is then used as an information shortcut — a heuristic — for far more complex judgments such as risk and benefit. Their formal definition: the affect heuristic is the reliance on positive or negative emotional reactions to objects to guide judgments and decisions, often in place of more deliberate analysis.
The chapter draws on a striking body of experimental evidence. In one classic study (Finucane, Alhakami, Slovic and Johnson, 2000, Journal of Behavioral Decision Making), participants who were nudged to feel positively about a technology rated its risks as lower and its benefits as higher — and the inverse for the negatively-nudged group. The dial moved in the affect-consistent direction even though the underlying technology was identical. Risk and benefit, which in objective reality are positively correlated (high-benefit activities tend to also be high-risk), get inversely yoked in the mind. This inverse risk-benefit confounding is the diagnostic fingerprint of the affect heuristic.
Slovic’s 2007 follow-up, “The Affect Heuristic” (European Journal of Operational Research, 177(3): 1333–1352), tightened the framing: when people make judgments under time pressure, cognitive load, or about unfamiliar technical content, they substitute a difficult question (“Is this stock a good long-term investment?”) with an easier one (“How does this stock make me feel?”). The substitution is invisible to the person doing it.
2. The Underlying Psychology — Why “Feel First” Wins
The affect heuristic is the operational side of what Daniel Kahneman, in Thinking, Fast and Slow (2011), calls System 1 — the fast, automatic, emotion-tagging machine that runs underneath conscious thought. Three psychological mechanisms compound to make it sticky:
(a) The somatic marker hypothesis. Antonio Damasio’s neuroscience research (1994, Descartes’ Error) showed that decisions are physically tagged in the body — gut tightness, chest warmth — long before the cortex catches up. Patients with damage to the ventromedial prefrontal cortex, who could not generate these somatic markers, became catastrophic decision-makers despite intact IQ. We literally feel our way through choices and rationalise afterwards.
(b) Cognitive miserliness. Stanovich and West (2008, Journal of Personality and Social Psychology) document that humans default to the lowest-effort cognitive route compatible with getting an answer. Affect is metabolically cheap; analysis is expensive. The brain, like a small-cap CFO, optimises working capital.
(c) The image-and-narrative pull. Slovic’s 2002 paper specifically highlights that affect attaches more readily to images, stories, and identifiable individuals than to statistics. Show an investor a chart of a stock that 10x’d, with a smiling founder photo: affect spikes positive. Show the same investor a base-rate table that 8 out of 10 small-caps in the same period delivered negative real returns: affect barely moves.
3. The Indian Manifestation — Affect-Driven Retail Behaviour in 2024–26
The Indian retail-investor explosion has produced an exceptionally rich natural experiment in the affect heuristic. Several data points anchor the picture:
NSE Annual Report 2023-24 records that retail investors hold 9.18% of total NSE-listed market capitalisation, the highest in over a decade, and that the median holding period in the cash market continues to fall. Faster turnover is an affect-heuristic signature: positions are formed and dissolved on emotional triggers rather than fundamentals.
SEBI’s 24 September 2024 update on F&O activity noted that 91.1% of individual traders in equity derivatives incurred net losses in FY24, with aggregate net losses of approximately ₹75,000 crore in that year alone, and ₹1.81 lakh crore over FY22–FY24. Equity F&O is the purest playground of the affect heuristic — the trader does not buy a business; she buys a feeling about a directional move, often catalysed by a 30-second WhatsApp forward.
Prof. V. Ravi Anshuman of IIM Bangalore, in his Centre for Capital Markets and Risk Management working paper series on Indian retail-investor behaviour, has documented that Indian retail flows into individual stocks are positively correlated with prior-quarter media mentions and brand visibility — an empirical correlate of affect-driven attention. The behavioural translation of Meir Statman’s work (Finance for Normal People, 2017) into the Indian context, which Anshuman’s group references, shows that Indian retail investors over-index on what Statman calls expressive and emotional benefits — the feeling of owning the brand of the soft drink they drank as children, the airline they last flew, the tractor company in their village — relative to utilitarian (return-on-capital) benefits.
Festival-season retail flow patterns reported by AMFI in its FY24 monthly bulletins show measurable spikes in equity-mutual-fund SIP registrations in Diwali and post-Diwali weeks — a textbook example of positive-affect priming spilling into financial commitment. The product is identical in October and February; the willingness to commit is not.
Stitching these together: the modal Indian retail investor in 2026 is operating on an affect heuristic at every stage — selecting a stock from a feeling, sizing the position from a feeling, and exiting on a feeling.
4. The Counter-Measure Checklist for the Indian Long-Term Investor
The affect heuristic cannot be abolished — it is wired into the nervous system. It can, however, be neutralised by interposing a deliberate System-2 process between the affective spark and the trading-app tap. The following nine-item checklist, adapted from Slovic’s “kill the messenger” framework and the operational discipline of Graham, Buffett and Klarman, is what we recommend:
1. Write the affect down before the analysis. Before opening the annual report, write one line: “My current emotional reaction to this stock is ___ because ___.” Naming the affect partially neutralises it (Lieberman et al., 2007, Psychological Science — affect labelling reduces amygdala response).
2. Replace the stock name with a code. When evaluating, refer to the company as “Company A”. The brand halo is the largest single contributor to affect contamination.
3. Calculate base rates first. What proportion of small-caps in this sector returned more than 0% real over 10 years? What proportion of capital-raising IPOs in this sector traded below issue price 5 years later? Base rates are unsexy; they are also, per Kahneman-Tversky, the single most under-weighted input in retail decisions.
4. Insist on a 10-year audited number sheet. Affect cannot survive 10-year revenue, profit, OCF, capex and dividend rows side-by-side. The eye is forced to System 2.
5. Run a pre-mortem. “It is 2031, the position is down 70%. What happened?” (See our 30 April post on Klein’s pre-mortem). Pre-mortems extinguish optimistic affect with corrosive specificity.
6. Separate buy logic from buy timing. Affect tries to compress both into one click. Force a 48-hour gap between deciding “this business is investable” and deciding “today is the day”.
7. Maintain a decision journal. Every entry must record: (i) the affective state at the time, (ii) the analytical reason, and (iii) the falsification condition. Reviewing the journal exposes the gap between feeling-driven and process-driven decisions.
8. Refuse to buy on the day of a positive news headline. Affect is highest immediately post-news. The 48-hour cooling rule eliminates 80% of FOMO-driven entries.
9. Bring a second pair of eyes. A spouse, friend, fellow investor — anyone who does not share your affective state — to read your buy thesis aloud. If it sounds like a feeling pretending to be a thesis, that is exactly what it is.
5. How the Greats Disarmed the Affect Heuristic
Benjamin Graham built the entire concept of “Mr. Market” (The Intelligent Investor, 1949, Chapter 8) explicitly to detach the investor from the affect of the daily quote. Mr. Market is portrayed as a manic-depressive — the personification of affect — whose moods are to be exploited, never imitated.
Warren Buffett, in his 1987 letter to Berkshire Hathaway shareholders: “Investing in a market where people believe in efficiency is like playing bridge with someone who has been told it doesn’t do any good to look at the cards.” His operational filter — the moat-and-management framework — is structurally affect-resistant: it asks for evidence of decade-long competitive advantage, not for a feeling about the stock.
Charlie Munger coined the phrase “the psychology of human misjudgment” (1995 Harvard Law speech). Among the 25 standard causes he listed, “excessive self-regard tendency” and “do-something tendency” are direct cousins of the affect heuristic. His prescription — checklists, inversion, multi-disciplinary mental models — is precisely the System-2 scaffolding the affect heuristic cannot penetrate.
Seth Klarman, in Margin of Safety (1991), writes that “the stock market is the story of cycles and of the human behaviour that is responsible for overreactions in both directions.” His Baupost discipline — buying only when the margin of safety mathematically exists, regardless of how the position “feels” — is anti-affect by construction.
6. Illustrative Case Study — How Titan Biotech Ltd (BSE: 524717) Exhibits Anti-Affect Behaviour at the Corporate Level
The following section is a process-level educational case study, not a recommendation, valuation, price target or commentary on the suitability of Titan Biotech for any reader’s portfolio. No buy/sell/hold view is offered or implied. The numbers below are taken from the audited consolidated financial statements in the Titan Biotech Ltd Annual Report 2024-25 and Screener.in. Investors are urged to consult their SEBI-registered investment advisor and conduct independent due diligence.
The affect heuristic at the company level shows up as: chasing exciting capex, optical revenue stretching, flashy diversification, leverage to amplify the “feel” of growth, and management compensation that rises with announcement-grade narrative rather than audited cash. A company that systematically does the opposite is, in behavioural-process terms, an anti-affect operator. Titan Biotech’s FY25 audited disclosures present an unusually clean illustration of that anti-affect template.
| Behavioural Marker | Titan Biotech FY25 Audited Number | Anti-Affect Interpretation |
|---|---|---|
| Borrowings discipline | ₹3 crore (FY25) vs ₹16 crore (FY21) — an 81% reduction over four years | Management refused to borrow to amplify “growth feel”; growth was funded from internal accruals. |
| Cash-backing of profits | CFO/Operating Profit = 103% (FY25), 85% (FY24), 97% (FY23) | Profits are real cash, not affective accruals. Three-year mean above 95% is a statistical signature of clean accounting. |
| Disclosed contingent risks | ₹7.78 crore (FY25), down from ₹12.90 crore (FY24); 5.08% of net worth | Symmetric disclosure of negative-affect items, with year-on-year progress, is anti-confirmation behaviour. |
| Capex pipeline | CWIP ₹4 crore (Sept 2025), peaked ₹13 crore (FY23); gross block ₹57 crore (FY25) vs ₹11 crore (FY15) | Steady, decade-long compounding of fixed assets; no big-bang affect-laden capex announcements. |
| Capital efficiency | RoCE 16.9%; RoE ~15%; 10-yr profit CAGR 29%; 5-yr profit CAGR 26% | Returns earned slowly and consistently — the antithesis of affect-driven, lump-and-promise growth. |
| Geographic risk distribution | Domestic ₹10,254.80 lakh + Overseas ₹5,390.28 lakh; ~34.5% export share, 60+ countries | Diversification by deliberate process, not by chase-the-hot-geography affect. |
| Quarterly revenue trajectory FY26 | Q1 ₹46.50 Cr → Q2 ₹54 Cr → Q3 ₹56 Cr (three consecutive QoQ increases) | Sequential, evidence-grade growth — the kind that resists the “where is the next inflection?” affective itch. |
| Board independence | 11 directors; 4 independent (36.4%); 2 women (18.2%); independent chair; 14 board meetings in FY25 | Structural affect-firewall: an independent chair and a third of the board outside the family is an anti-self-regard feature. |
| Depreciation conservatism | Depreciation ratio FY25 ~7.0% of gross block, vs sector peers ~4–5% | Aggressive depreciation reduces reported profit today — exactly what affect-driven managements avoid because it dampens narrative. |
Stitched together, the nine markers describe a corporate operating system that earns return on capital (16.9% RoCE) on a fortress balance sheet (₹3 crore borrowings against ₹1,779 crore market cap as of 15 April 2026), generates 103% cash backing on operating profit, and discloses negative-affect items (contingent liabilities, depreciation conservatism) with the same care as positive-affect items. That is, in behavioural-finance language, an organisation whose disclosure architecture is engineered to resist the affect heuristic at the source — at the level of the management’s own decisions.
Crucially, none of this implies anything about the price at which the stock trades, the multiple it deserves, or whether any reader should buy, sell, or hold the security. The case study is offered solely as an illustration of how the lesson of Slovic et al. (2002) translates from individual investor decision-making into corporate-process discipline.
7. Key Takeaways for the Indian Long-Term Investor
(i) The affect heuristic — feel first, justify second — is the most pervasive and least visible cognitive shortcut in investing. Slovic et al. (2002) show that under time pressure or cognitive load, affect literally substitutes for analysis.
(ii) Indian retail data — 91.1% F&O loss rate, ₹1.81 lakh crore aggregate F&O losses, festival-driven SIP spikes, falling cash-market holding periods — is consistent with widespread affect-driven decision-making.
(iii) The counter-measure is a System-2 scaffold: name the affect, replace the brand with a code, calculate base rates, run a pre-mortem, separate buy-logic from buy-timing, and maintain a decision journal.
(iv) Graham, Buffett, Munger and Klarman each built operating frameworks — Mr. Market, moat-and-management, multidisciplinary checklists, margin of safety — that are anti-affect by construction.
(v) Titan Biotech (BSE: 524717) FY25 illustrates corporate anti-affect behaviour: ₹3 crore borrowings (down from ₹16 crore in FY21, an 81% decline), 103% CFO/Operating Profit, RoCE 16.9%, contingent liabilities of just ₹7.78 crore (5.08% of net worth, down 39.7% YoY), three consecutive QoQ revenue increases (₹46.5 Cr → ₹54 Cr → ₹56 Cr), 36.4% independent directors with an independent chair, and a deliberately conservative ~7% depreciation ratio — a process-level anti-affect template.
(vi) The investor’s job is not to feel less. It is to install enough System-2 friction between the feeling and the click that the feeling is allowed to inform but never to decide.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
